{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03941860","nct_id":"NCT03941860","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03941860. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.","label":"Arm A (lenalidomide, ixazomib citrate)","type":"EXPERIMENTAL"},{"description":"Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.","label":"Arm B (lenalidomide, placebo)","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-01-31","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":1,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Marrow Aspirate","otherNames":["BONE MARROW, LIQUID","Human Bone Marrow Aspirate"],"type":"PROCEDURE"},{"name":"Bone Marrow Biopsy","otherNames":["Biopsy of Bone Marrow","Biopsy, Bone Marrow"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Ixazomib Citrate","otherNames":["MLN 9708","MLN-9708","MLN9708","Ninlaro"],"type":"DRUG"},{"name":"Lenalidomide","otherNames":["CC 5013","CC-5013","CC5013","CDC 501","Revlimid"],"type":"DRUG"},{"name":"Placebo Administration","otherNames":[],"type":"OTHER"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging","PT"],"type":"PROCEDURE"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2025-05-23","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization."}],"references":[],"start_date":{"date":"2022-02-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial","url":"https://clinicaltrials.gov/study/NCT03941860"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03941860"}